NDRA
ENDRA Life Sciences Inc.Company Information
- Company Name
- ENDRA Life Sciences Inc.
- CIK
- CIK0001681682
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- NDRA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 3845
- SIC Description
- Electromedical & Electrotherapeutic Apparatus
- Ticker
- NDRA
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-08-27
- Last sale
- —
- Shares purchased (TTM)
- 3,715
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 153,657
- Shares outstanding
- 1,324,046
- Ownership
- 11.61%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- 35.35%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Convertible Preferred Stock | - | - | - | - | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | ||||||
| Series B Convertible Preferred Stock | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Series A Preferred Stock | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | - | 0 | - | - | ||||||
| Series B Preferred Stock | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | - | - | ||||||
| Series C Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | ||||||
| Series C Convertible Preferred Stock | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 6 | 1 | 1 | 1 | 2 | 2 | 3 | 5 | 7 | 1 | 3 | 6 | ||||||
| Cash And Cash Equivalents At Carrying Value | 2 | 0 | 1 | 1 | 2 | 2 | 3 | 5 | 6 | 1 | 3 | 3 | ||||||
| Restricted Cash Current | 4 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Inventory Net | - | - | 0 | - | - | - | 0 | 3 | 3 | 3 | 3 | 3 | ||||||
| Other Assets | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
| Crypto Asset Fair Value Current | 2 | 2 | 2 | - | - | - | - | - | - | - | - | - | ||||||
| Assets | 8 | 3 | 4 | 2 | 3 | 3 | 4 | 8 | 10 | 5 | 7 | 8 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Short Term Borrowings | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts Payable And Accrued Liabilities Current | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
Long Term Debt | ||||||||||||||||||
| Long Term Debt | - | - | - | - | - | - | 0 | - | - | 0 | 0 | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Contract With Customer Liability | - | - | - | - | 0 | 0 | - | 1 | - | - | - | - | ||||||
| Preferred Stock Value | - | - | - | - | - | 0 | - | - | - | - | - | - | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Liabilities Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Derivative Liabilities Noncurrent | 1 | 0 | 0 | 1 | - | - | 1 | - | - | - | - | - | ||||||
| Liabilities | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 6 | 2 | 2 | 0 | 1 | 2 | 3 | 7 | 9 | 4 | 6 | 5 | ||||||
| Additional Paid In Capital | 118 | 114 | 113 | 107 | 107 | 106 | 106 | 106 | 106 | 98 | 98 | 96 | ||||||
| Retained Earnings Accumulated Deficit | -112 | -112 | -110 | -107 | -106 | -104 | -103 | -99 | -97 | -95 | -92 | -90 | ||||||
| Liabilities And Stockholders Equity | 8 | 3 | 4 | 2 | 3 | 3 | 4 | 8 | 10 | 5 | 7 | 8 | ||||||
| Preferred Class B | - | - | - | - | 0 | 0 | - | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 1,000 | 1,000 | 1,000 | 20 | 20 | 20 | 1,000 | 20 | 1,000 | 80 | 20 | 80 | ||||||
| Common Stock Shares Issued | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 55 | 11 | 6 | 8 | ||||||
| Shares Outstanding | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 72 | 11 | 6 | 8 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | - | - | - | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialENDRA Life Sciences Inc. (NDRA) — SEC Financial Statements & Analysis
ENDRA Life Sciences Inc. (NDRA) is a electromedical & electrotherapeutic apparatus company, incorporated in DE. ENDRA Life Sciences Inc. trades on Nasdaq as: NDRA. ENDRA Life Sciences Inc. (NDRA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, ENDRA Life Sciences Inc. carries a market cap of $7.06M, a P/E ratio of -1.19x, a P/B ratio of 1.12x, an enterprise value of $1.52M, and an EV/EBITDA multiple of -0.23x. On profitability, it posts a Return on Equity (ROE) of -152.04%, a Return on Assets (ROA) of -110.08%, and a Return on Invested Capital (ROIC) of -3062.12%. Per share, it reports EPS of $-4.47, diluted EPS of $-2.39, free cash flow per share of $-3.66, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -32.50% year-over-year and EPS growth of -63.44% year-over-year. On the balance sheet, it maintains a current ratio of 7.10x, a quick ratio of 7.04x, working capital of $4.80M, a debt-to-equity ratio of 0.26x, a debt ratio of 0.21, free cash flow of $-4.84M (TTM), and net debt of $-5.54M. Figures sourced from SEC EDGAR.
- Market Cap
- $7.06M
- P/E TTM
- -1.19x
- EPS TTM
- $-4.47
- P/B TTM
- 1.12x
- ROE TTM
- -152.04%
- ROA TTM
- -110.08%
- Debt To Equity
- 0.26x
- Free Cash Flow TTM
- $-4.84M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ENDRA Life Sciences Inc. in?
ENDRA Life Sciences Inc. (NDRA) operates in the Electromedical & Electrotherapeutic Apparatus industry.
What exchange does NDRA trade on?
ENDRA Life Sciences Inc. (NDRA) trades on the Nasdaq.
Where is ENDRA Life Sciences Inc. incorporated?
ENDRA Life Sciences Inc. is incorporated in DE.
When was ENDRA Life Sciences Inc. (NDRA)'s most recent SEC filing?
ENDRA Life Sciences Inc. (NDRA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is NDRA's market cap?
ENDRA Life Sciences Inc. (NDRA) has a market capitalization of $7.06M as of 2026-06-30.
What is NDRA's EPS (earnings per share)?
ENDRA Life Sciences Inc. (NDRA)'s trailing twelve month EPS is $-4.47 as of 2026-06-30.
What is NDRA's ROE (return on equity)?
ENDRA Life Sciences Inc. (NDRA)'s trailing twelve month Return on Equity (ROE) is -152.04% as of 2026-06-30.
What is NDRA's ROA (return on assets)?
ENDRA Life Sciences Inc. (NDRA)'s trailing twelve month Return on Assets (ROA) is -110.08% as of 2026-06-30.
What is NDRA's ROIC (return on invested capital)?
ENDRA Life Sciences Inc. (NDRA)'s trailing twelve month Return on Invested Capital (ROIC) is -3062.12% as of 2026-06-30.
What is NDRA's EV/EBITDA?
ENDRA Life Sciences Inc. (NDRA)'s trailing twelve month EV/EBITDA is -0.23x as of 2026-06-30.